白云山：子公司药物儿童小柴胡颗粒进入Ⅱ期临床试验

Core Viewpoint - Baiyunshan (600332) announced that its subsidiary Guanghua Pharmaceutical has recently registered the Phase II clinical trial information for its children's Xiao Chai Hu granules on the National Medical Products Administration's clinical trial registration and information disclosure platform [1] Group 1 - The announcement was made on September 22 [1] - The product in focus is children's Xiao Chai Hu granules, which is a traditional Chinese medicine [1] - The registration of the clinical trial indicates progress in the development of this pediatric medication [1]